Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor—estrogen receptor β

Molecular Carcinogenesis

Volumn 55, Issue 11, 2016, Pages 1843-1857

  Sharma, Vikas ^a   Verma, Vikas ^a   Lal, Nand ^a   Yadav, Santosh K ^a   Sarkar, Saumya ^a   Mandalapu, Dhanaraju ^a   Porwal, Konica ^a   Rawat, Tara ^a   Maikhuri, J P ^a   Rajender, Singh ^a   Sharma, V L ^a   Gupta, Gopal ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

cell proliferation; disulfiram; DNMT1; estrogen receptor ; prostate cancer

Indexed keywords

AZACITIDINE; COMPOUND 339; DISULFIRAM; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; METHYL GROUP; UNCLASSIFIED DRUG; DMAP1 PROTEIN, HUMAN; ENZYME INHIBITOR; ESR2 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIZATION; ENZYME INHIBITION; ENZYME MECHANISM; EPIGENETICS; HUMAN; HUMAN CELL; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PROSTATIC NEOPLASMS; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISULFIRAM; ENZYME INHIBITORS; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MOLECULAR DOCKING SIMULATION; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84989291067     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22433     Document Type: Article

References (47)

1. Drudge-Coates L, Turner B. Prostate cancer overview. Part 1: Non-metastatic disease. Br J Nurs 2012; 21:S23–S28.
2. Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: Genomic alterations and heterogeneity. Nat Rev Urol 2012; 9:652–664.
3. Perry AS, Watson RW, Lawler M, Hollywood D. The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol 2010; 7:668–680.
4. Das PM, Singal R. DNA methylation and cancer. J ClinOncol 2004; 22:4632–4642.
5. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27–36.
6. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64:1975–1986.
7. Yegnasubramanian S, Haffner MC, Zhang Y, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008; 68:8954–8967.
8. Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology 2009; 150:3991–4002.
9. Nelson WG, Yegnasubramanian S, Agoston AT, et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 2007; 12:4254–4266.
10. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97:103–115.
11. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation, and gene expression in cancer. Hum Mol Genet 2001; 10:687–692.
12. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349:2042–2054.
13. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148–1159.
14. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93:5925–5930.
15. Li LC, Yeh CC, Nojima D, Dahiya R. Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun 2000; 275:682–689.
16. Sasaki M, Tanaka Y, Perinchery G, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. J Natl Cancer Inst 2002; 94:384–390.
17. Zhu X, Leav I, Leung YK, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 2004; 164:2003–2012.
18. Nojima D, Li LC, Dharia A, et al. CpGhypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma. Cancer 2001; 92:2076–2083.
19. Nakayama T, Watanabe M, Suzuki H, et al. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 2000; 80:1789–1796.
20. Lin J, Haffner MC, Zhang Y, et al. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth 2011. Prostate 2011; 71:333–343.
21. Veverka KA, Johnson KL, Mays DC, Lipsky JJ, Naylor S. Inhibition of aldehyde dehydrogenase by disulfiram and its metabolite methyl diethylthiocarbamoyl-sulfoxide. Biochem Pharmacol 1997; 53:511–518.
22. Pradhan M, Esteve PO, Chin HG, Samaranayke M, Kim GD, Pradhan S. CXXC domain of human DNMT1 is essential for enzymatic activity. Biochemistry 2008; 47:10000–10009.
23. Jung Y, Park J, Kim TY, et al. Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy. J Mol Med 2007; 85:1137–1148.
24. Song J, Rechkoblit O, Bestor TH, Patel DJ. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science 2011; 331:1036–1040.
25. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997; 18:2714–2723.
26. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 2009; 30:2785–2791.
27. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera—A visualization system for exploratory research and analysis. J Comput Chem 2004; 25:1605–1612.
28. Mack GS. Epigenetic cancer therapy makes headway. J Natl Cancer Inst 2006; 98:1443–1444.
29. Iljin K, Ketola K, Vainio P, et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res 2009; 15:6070–6078.
30. Wickstrom M, Danielsson K, Rickardson L, et al. Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients. Biochem Pharmacol 2007; 73:25–33.
31. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006; 66:10425–10433.
32. Lovborg H, Oberg F, Rickardson L, Gullbo J, Nygren P, Larsson R. Inhibition of proteasome activity, nuclear factor-KappaB translocation, and cell survival by the anti-alcoholism drug disulfiram. Int J Cancer 2006; 118:1577–1580.
33. Cho HJ, Lee TS, Park JB, et al. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 2007; 40:1069–1076.
34. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003; 104:504–511.
35. Brar SS, Grigg C, Wilson KS, et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther 2004; 3:1049–1060.
36. Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a, and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res 2000; 28:2108–2113.
37. Zhang X, Leung YK, Ho SM. AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells. Oncogene 2007; 26:7346–7354.
38. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpGisland marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994; 54:2552–2555.
39. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7:536–540.
40. McPherson SJ, Hussain S, Balanathan P, et al. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated. Proc Natl Acad Sci USA 2010; 107:3123–3128.
41. Muthusamy S, Andersson S, Kim HJ, et al. Estrogen receptor beta and 17beta-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer. Proc Natl Acad Sci USA 2011; 108:20090–20094.
42. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P. Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 2004; 11:537–551.
43. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. Faseb J 2008; 22:1512–1520.
44. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor-beta potency-selective ligands: Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 2001; 44:4230–4251.
45. Meyers MJ, Sun J, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor subtype-selective ligands: Asymmetric synthesis and biological evaluation of cis- and trans-5, 11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. J Med Chem 1999; 42:2456–2468.
46. Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, Katzenellenbogen BS. Antagonists selective for estrogen receptor alpha. Endocrinology 2002; 143:941–947.
47. Godley LA, Mondragon A. Molecular biology. Preference by exclusion. Science 2011; 331:1017–1018.